Peptide Cycling Protocols: How Long to Run Each Peptide and When to Take a Break

At a Glance

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Knowing what peptide to use is only half the equation. The other half — when to start, when to stop, and when to restart — determines whether a course produces durable benefit or merely temporary noise. Two failure patterns are common: people who discontinue a peptide after two weeks because “it didn’t do anything,” and people who run the same peptide indefinitely until its effects plateau and eventually vanish. Both patterns stem from the same misunderstanding: peptides are modulators, not replacements, and the receptor biology that makes them effective is also the biology that argues for structured timing.

This article covers the pharmacological basis for cycling, what the human evidence on desensitisation actually shows, the schedules most commonly used for the main therapeutic peptides, how to read clinical signals that indicate a cycle is working, and how to sequence breaks. Be clear about one thing from the start: no controlled human study has compared an on/off schedule with continuous use, or with no treatment, for BPC-157, TB-500, CJC-1295, ipamorelin, epithalon or thymosin alpha 1 outside approved indications. The schedules below are practice conventions, not trial results.

Why Cycling Matters: Receptor Biology and Tachyphylaxis

Receptor Downregulation

Prolonged agonist exposure at many receptor classes tends to produce compensatory downregulation. The cell internalises surface receptors (endocytosis), reduces receptor mRNA transcription, and shifts intracellular signalling downstream. The result is progressive attenuation — what clinicians recognise as tachyphylaxis and patients describe as “the peptide stopped working.” Clinicians see this with nitrates, with some opioids and with continuous GnRH agonists, which are used deliberately to shut down the pituitary.

Growth hormone secretagogues (GHS-R1a agonists such as ipamorelin and GHRP-6) are the usual example given for peptides. The GHRH analogue CJC-1295 with Drug Affinity Complex (DAC) produces a continuous bleed of GHRH signalling for 7–14 days after a single injection, which is one reason pulsatile dosing schedules (5 on / 2 off) are preferred over daily injections with the non-DAC version.

What the Human Evidence Shows

The best-studied case is the pituitary GH axis, because approved and investigational GH-releasing drugs have been tested in people. The data show less desensitisation than cycling theory predicts:

For tesamorelin, an FDA-approved GHRH analogue for HIV-associated abdominal fat, reduced visceral fat was sustained over 52 weeks of continuous treatment, and fat reaccumulated after the drug was stopped [4]. For approved drugs, the prescribing information sets the duration.

So the stronger argument for breaks on GH secretagogues is not rapid tachyphylaxis. It is that sustained GH-axis stimulation has measurable metabolic effects (rising glucose, falling insulin sensitivity [3]), and a structured break is a natural point to check them.

Why Repair Peptides Are Also Cycled

BPC-157 and TB-500 operate through distinct but overlapping mechanisms — VEGF upregulation, eNOS activation, and actin remodelling — and are less susceptible to classical receptor downregulation than GHS-R1a agonists. The reason for a defined course is different: the repair processes they are used to support are finite. Fibroblast proliferation, angiogenesis, and ECM remodelling have a natural arc — they ramp up, plateau, and consolidate. Continuing BPC-157 once acute tissue repair is complete adds cost without a clear reason. The “cycle” for repair peptides is therefore less about preventing tachyphylaxis and more about aligning administration to the biological repair arc.

There are no human pharmacokinetic, dose-finding or schedule studies for BPC-157 or TB-500. The total human evidence for BPC-157 is three small, poor-quality studies with 30 participants [6].

The Practical Case for Structured Breaks

Structured cycling is also meant to preserve the “dynamic range” of a peptide, so that the next course produces a first-use effect rather than an already-blunted response, and to create fixed points for reassessment. This logic has not been tested in a controlled human study, but it keeps total exposure to products with no long-term safety data as short as possible.

Cycling Schedules by Peptide

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

BPC-157 Cycling

Standard Acute Protocol

BPC-157 (Body Protection Compound-157) is most commonly used for musculoskeletal injury, gut healing, and systemic tissue repair. The standard acute cycle used in practice:

• Duration: 4–6 weeks for acute injury; up to 8 weeks for chronic or complex pathology
• Break: Minimum 4 weeks; 4–6 weeks is common
• Restart criteria: Recurrence of symptoms, new injury, or gut inflammation flare

In acute Achilles tendinopathy or post-surgical recovery, four weeks of subcutaneous BPC-157 at 250–500 mcg/day is the usual course. Users typically report the most change in the first 2–3 weeks; weeks 4–6 are meant to consolidate gains. Continuing beyond 8 weeks without a clear therapeutic target rarely makes sense.

Chronic and Maintenance Use

For chronic conditions — refractory gut pathology (Crohn’s, post-infectious IBS), persistent neuropathy, or recurrent musculoskeletal breakdown — some practitioners use a maintenance pattern of 2–4 weeks on, 2 weeks off, cycled indefinitely. The evidence base for indefinite cycling is largely mechanistic and case-series level; if this approach is used at all, it should be selective, with a treatment reassessment every 12 weeks to determine whether maintenance remains justified.

Oral vs Subcutaneous Cycling

Oral BPC-157 (for gut-specific indications) follows the same cycle logic but with lower systemic exposure. For gut-targeted use the oral cycle is often extended to 8–10 weeks before a 4-week break, on the rationale that intestinal exposure differs from systemic subcutaneous delivery.

TB-500 (Thymosin β4) Cycling

TB-500 is a synthetic fragment of Thymosin β4, primarily used for soft-tissue injury, tendon repair, and post-surgical recovery. Its cycling structure differs from BPC-157 because it uses a distinct frontloading phase:

Loading and Maintenance Phases

• Loading phase: 2–4 mg twice per week for 4–6 weeks (this is the active healing window)
• Maintenance phase (optional): 2 mg once per week or 2 mg twice per month for 4–6 weeks following the load
• Break: 4–6 weeks after the maintenance phase; restart only when there is a new injury or clinical indication

The loading phase is meant to drive the acute angiogenic and actin-remodelling effects. Many users are tempted to continue at loading doses beyond six weeks — this is rarely justified and significantly increases cost. The maintenance dose is not about ongoing tissue repair; it is about allowing consolidation of the new extracellular matrix laid down during the loading phase.

When No Maintenance Is Needed

For acute, well-defined injuries (e.g., muscle tear, ligament sprain), TB-500 is often used without a formal maintenance phase: four weeks of loading at 2 mg twice weekly, then a clean break. In rat wound models, full-length thymosin β4 increased re-epithelialisation within 4 to 7 days of administration [12] — consistent with a front-loaded, time-limited course rather than ongoing dosing.

CJC-1295 / Ipamorelin Cycling

This combination remains the most widely used growth hormone secretagogue stack in integrative medicine. The cycling structure must account for pituitary somatotroph sensitivity and metabolic effects as the governing constraints.

Standard 12–16 Week Cycle

• Cycle length: 12–16 weeks
• Break: 4–8 weeks (6 weeks is a common choice)
• Timing within a day: Dosing immediately before sleep (peak GH pulse is nocturnal) and optionally at a second pulse point before exercise

During the 12–16 week active cycle, a 5 days on / 2 days off pattern is used to maintain pulsatile sensitivity better than 7-days-per-week dosing. The two-day rest is intended to allow partial recovery of GHS-R1a expression.

Monitoring During a Cycle

IGF-1 is usually checked at baseline, at week 6, and at the end of the cycle. A target IGF-1 range of 200–300 ng/mL in adults under 60 (age-adjusted downward) signals adequate GH axis stimulation without excess. If IGF-1 rises above the age-adjusted upper normal range, the dose or frequency is reduced before the break — not after. Glucose and HbA1c belong on the same panel [3].

Post-Cycle Considerations

Unlike anabolic steroids, peptide-based GH secretagogues do not suppress the hypothalamic-pituitary axis through negative feedback in the same way exogenous GH does — they work by amplifying endogenous pulsatile secretion [2]. Post-cycle GH axis recovery is typically rapid (within 2–4 weeks of stopping), and a structured 4–8 week break is used before the next cycle.

Sermorelin Cycling

Sermorelin (GHRH 1-29) has a shorter half-life than CJC-1295 DAC, making it more forgiving of daily dosing and less prone to tachyphylaxis accumulation between doses [13]. However, extended continuous use is still usually cycled.

Longer Cycles, Shorter Breaks

• Cycle length: 12–24 weeks (sermorelin is often used in longer courses because its shorter half-life produces less receptor saturation)
• Break: 4 weeks minimum; some protocols use 4 weeks on / 1 week off for extended maintenance
• Ongoing monitoring: IGF-1 every 3 months during active cycles

People over 50 on sermorelin as part of an anti-aging protocol often run 6-month active cycles (5 days on / 2 off) followed by a 4-week break before reassessment. This is the closest to a “maintenance” pattern used for any GH secretagogue, and the rationale is sermorelin’s short half-life (approximately 10–20 minutes), which limits continuous receptor stimulation between daily doses.

Epithalon Cycling

Epithalon (Epitalon, tetrapeptide Ala-Glu-Asp-Gly) is proposed to act through an entirely different mechanism — telomerase activation in cell studies [7] and modulation of pineal gland function — and is used in a pulsed annual protocol rather than continuous cycling.

Annual Pulse Protocol

• Course structure: 5–20 mg per day (typically 10 mg/day subcutaneous) for 10 consecutive days
• Frequency: Once or twice per year
• Break: 6–12 months between courses (some anti-aging protocols use 6-month intervals; the original Khavinson research used annual courses)

The rationale for annual pulsing derives from Khavinson’s research: the idea is that short, intensive courses set the pineal gland’s regulatory effects in motion, rather than continuous stimulation. That work rests on cell and animal studies [7][8]; in the key mouse study, mean lifespan did not change and only the longest-lived animals lived longer [8]. No controlled human trial has tested the schedule, and re-dosing before 6 months has no long-term safety data to support it.

Thymosin Alpha-1 Cycling

Thymosin Alpha-1 (Tα1) is an immunomodulatory peptide used in chronic infections (Lyme disease, viral reactivation), post-viral immune dysfunction, and as adjunct therapy in cancer support. Its cycling structure reflects its intended role in recalibrating Th1/Th2 balance rather than driving acute repair. Where Tα1 is licensed, the label sets the regimen; in a large sepsis trial it did not reduce mortality [9].

Standard Immune-Modulation Cycle

• Cycle length: 6–12 weeks at 1.6 mg twice weekly (the labelled hepatitis B dose where Tα1 is licensed)
• Break: 4–8 weeks; reassess immune markers (NK cell function, CD57, cytokine panel) before restart
• Chronic low-dose maintenance: 1.6 mg once weekly is used in some chronic infection protocols between active cycles; this is off-label and monitored every 3 months

For Lyme disease or post-viral immune dysfunction, the protocols in circulation typically use a 12-week active course, then a 4-week break with immune marker reassessment. If NK cell function and CD57 have normalised, there is no automatic restart — the goal is immune recalibration, not indefinite support. See also Thymosin Alpha-1 for Long COVID for post-viral applications.

Stacking Cycles: Aligning Multiple Peptides in Time

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

When two or more peptides are used simultaneously, cycle synchronisation matters. The most common scenario is BPC-157 + TB-500 for injury, often used alongside CJC-1295/Ipamorelin for accelerated recovery.

Practical approach:

1. Start BPC-157 and TB-500 together at injury onset (they share a cycle arc)
2. If adding a GH secretagogue, begin the 12-week CJC/Ipamorelin cycle at week 2 of the BPC-157/TB-500 course (after tolerability of the repair peptides is confirmed)
3. End BPC-157 and TB-500 at week 6 (loading complete)
4. Continue CJC/Ipamorelin through week 14
5. Break all peptides simultaneously for 4–6 weeks before reassessment

This phased approach avoids the confusion of multiple overlapping cycle endpoints and makes it easier to attribute clinical changes to specific agents. Every added peptide adds its own unknowns; there is no human safety data on these combinations.

For a detailed guide to which peptides are combined, see Peptide Stacking: A Physician’s Guide.

Clinical Signals That a Cycle Is Working

Cycling decisions should be guided by clinical response, not just calendar time. Signs that an active cycle is producing meaningful benefit and should continue to its target duration:

• BPC-157 / TB-500: Reduced pain scores at 2 weeks, measurable improvement in range of motion or function by week 4, normalising inflammatory markers if tracked
• GH secretagogues: IGF-1 rising toward optimal range by week 6, improved sleep quality and body composition by week 8–10, lean mass gains confirmed by DEXA
• Thymosin Alpha-1: NK cell activity or CD57 trending upward at week 6, reduction in viral load (in HHV-6 or EBV reactivation), subjective energy improvement

Conversely, if there is no measurable or symptomatic response by week 4 for repair peptides (or week 8 for GH secretagogues), re-evaluate: consider whether the diagnosis driving the indication is accurate, whether the peptide source and reconstitution quality are reliable, and whether route of administration is appropriate before concluding the peptide is ineffective.

Known Risks

• Metabolic effects of GH stimulation. Rising glucose and falling insulin sensitivity with a GH secretagogue over 12 months [3].
• Serious adverse events. The FDA reports serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction, and serious adverse events including death when ipamorelin was given intravenously for gastric motility [10].
• Repeated exposure to poor-quality products. Test purchases of injectable peptides from online sellers have found purity far below the label and endotoxin in every sample [11].
• False reassurance. A break between courses does not make an impure or untested product safe during the weeks it is used, and “I only use it in cycles” should not replace the question that matters: does this person need this drug at all?

Regulatory Status

• United States. FDA’s page on bulk substances that may present significant safety risks (content current as of 22 April 2026) lists BPC-157, TB-500, CJC-1295, epitalon, ipamorelin and thymosin alpha 1, among others, as substances previously in category 2 whose compounding nominations were withdrawn [10]. None is in 503A category 1 as of FDA’s May 2026 list. Tesamorelin is an approved drug.
• EU and Germany. None of the unapproved peptides discussed here is authorised by the EMA or Germany’s BfArM.
• Sport. WADA 2026 prohibits BPC-157 (S0), TB-500 (S2.3) and GHRH analogues and GH secretagogues including CJC-1295, sermorelin, tesamorelin, ipamorelin and ibutamoren (S2.2.4).

When to Talk to a Physician

• If you are on an approved peptide medicine, ask your prescriber how long treatment should last and what will tell you it is working or should stop.
• If you are using an unapproved peptide in cycles, tell your physician. Ask for the relevant checks, for example IGF-1, glucose and HbA1c with GH secretagogues.
• Seek care for palpitations, flushing with dizziness, signs of infection at an injection site, or new swelling and joint pain.
• For investigational peptides, look for a registered trial on ClinicalTrials.gov or the EU Clinical Trials Register.

The Bottom Line

Repair peptides (BPC-157, TB-500) are typically run in 4–8 week courses with 4-week breaks, GH secretagogues in 12–16 week cycles with 4–8 week rests, and epithalon as an annual 10-day pulse. These schedules are practice conventions built on receptor biology and the repair arc, not on trials comparing cycled with continuous use. Where the GH axis has been studied in people, rapid desensitisation did not appear, while metabolic effects did, which is why monitoring matters more than the calendar.

Related Articles

• Peptide Stacking: A Physician’s Guide to Combining BPC-157, TB-500, and GHK-Cu
• BPC-157 Dosage and Protocol Guide
• CJC-1295 and Ipamorelin: Dosage and Protocol
• Sermorelin: Full Clinical Guide
• Thymosin Alpha-1 for Long COVID